|Epigenetic reprogramming of cancer cells via targeted DNA methylation|
AG Rivenbark, S Stolzenburg, AS Beltran, X Yuan, MG Rots, BD Strahl, ...
Epigenetics 7 (4), 350-360, 2012
|Inhibition of lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains|
TJ Stuhlmiller, SM Miller, JS Zawistowski, K Nakamura, AS Beltran, ...
Cell reports 11 (3), 390-404, 2015
|Breastmilk is a novel source of stem cells with multilineage differentiation potential|
F Hassiotou, A Beltran, E Chetwynd, AM Stuebe, AJ Twigger, P Metzger, ...
Stem cells 30 (10), 2164-2174, 2012
|Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer|
S Stolzenburg, MG Rots, AS Beltran, AG Rivenbark, X Yuan, H Qian, ...
Nucleic acids research 40 (14), 6725-6740, 2012
|Enhancer remodeling during adaptive bypass to MEK inhibition is attenuated by pharmacologic targeting of the P-TEFb complex|
JS Zawistowski, SM Bevill, DR Goulet, TJ Stuhlmiller, AS Beltran, ...
Cancer discovery 7 (3), 302-321, 2017
|Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors|
A Beltran, S Parikh, Y Liu, BD Cuevas, GL Johnson, BW Futscher, ...
Oncogene 26 (19), 2791-2798, 2007
|Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor|
AS Beltran, AG Rivenbark, BT Richardson, X Yuan, H Quian, JP Hunt, ...
Breast cancer research 13 (5), 1-21, 2011
|Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer|
S Stolzenburg, AS Beltran, T Swift-Scanlan, AG Rivenbark, R Rashwan, ...
Oncogene 34 (43), 5427-5435, 2015
|Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function|
AS Beltran, LM Graves, P Blancafort
Oncogene 33 (39), 4767-4777, 2014
|Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor|
AS Beltran, X Sun, PM Lizardi, P Blancafort
Molecular cancer therapeutics 7 (5), 1080-1090, 2008
|Suppression of breast tumor growth and metastasis by an engineered transcription factor|
AS Beltran, A Russo, H Lara, C Fan, PM Lizardi, P Blancafort
PloS one 6 (9), e24595, 2011
|EMX2 is epigenetically silenced and suppresses growth in human lung cancer|
J Okamoto, T Hirata, Z Chen, HM Zhou, I Mikami, H Li, A Beltran, ...
Oncogene 29 (44), 5969-5975, 2010
|Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors|
H Lara, Y Wang, AS Beltran, K Juárez-Moreno, X Yuan, S Kato, ...
Journal of Biological Chemistry 287 (35), 29873-29886, 2012
|Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs)|
AS Beltran, P Blancafort
Epigenetics 6 (2), 224-235, 2011
|Expression of the pluripotency transcription factor OCT4 in the normal and aberrant mammary gland|
F Hassiotou, A Hepworth, A Beltran, M Mathews, A Stuebe, P Hartmann, ...
Frontiers in oncology 3, 48555, 2013
|GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer|
SM Bevill, JF Olivares-Quintero, N Sciaky, BT Golitz, D Singh, AS Beltran, ...
Molecular Cancer Research 17 (7), 1503-1518, 2019
|Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients|
D Torres, JL Bermejo, MU Rashid, I Briceño, F Gil, A Beltran, V Ariza, ...
Scientific reports 7 (1), 4713, 2017
|Site-specific phosphorylation and caspase cleavage of GFAP are new markers of Alexander disease severity|
RA Battaglia, AS Beltran, S Delic, R Dumitru, JA Robinson, P Kabiraj, ...
Elife 8, e47789, 2019
|Pathogenic SPTBN1 variants cause an autosomal dominant neurodevelopmental syndrome|
MA Cousin, BA Creighton, KA Breau, RC Spillmann, E Torti, S Dontu, ...
Nature genetics 53 (7), 1006-1021, 2021
|Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions|
A Beltran, Y Liu, S Parikh, B Temple, P Blancafort
Assay and drug development technologies 4 (3), 317-331, 2006